Table 2.
Response and clinical benefit by risk category for all patients (n = 810)
| Best response | Favorable (n = 249) | Intermediate (n = 480) | Poor risk (n = 81) |
|---|---|---|---|
| CR | 9 (3.6%) | 34 (7%) | 1 (1.2%) |
| PR | 52 (21%) | 91 (19%) | 13 (16%) |
| SD | 128 (51.4%) | 185 (38.5%) | 24 (30%) |
| PD | 48 (19%) | 135 (28%) | 34 (42%) |
| Missing | 12 (5%) | 35 (7.3%) | 9 (11%) |
| CR + PR | 61 (24.5%) | 125 (26%) | 14 (17.3%) |
| CR + PR + SD | 189 (75.9%) | 310 (64.6%) | 38 (46.9%) |
CR complete response, PR partial response, SD stable disease, PD progressive disease